Treating Unresectable Early-Stage NSCLC

Opinion
Video

Patrick Forde, MBBCh, and the Oncology Brothers discuss treatment practices for patients with unresectable non–small cell lung cancer.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
4 experts in this video
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
4 experts in this video
Related Content
No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.

SC Amivantamab Consistent with IV Formulation in EGFR-Mutated NSCLC

Roman Fabbricatore
September 12th 2025
Article
Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Jacob Sands, MD
September 12th 2025
Podcast
Frontline Aumolertinib/Chemo Yields PFS Superiority in EGFR+ NSCLC

Frontline Aumolertinib/Chemo Yields PFS Superiority in EGFR+ NSCLC

Jax DiEugenio
September 12th 2025
Article
Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
September 12th 2025
Podcast
Concurrent Durvalumab Plus Chemo/RT Does Not Improve Efficacy in Stage III NSCLC

Concurrent Durvalumab Plus Chemo/RT Does Not Improve Efficacy in Stage III NSCLC

Ariana Pelosci
September 12th 2025
Article
The safety and tolerability of nivolumab/chemotherapy in non–small cell lung cancer were manageable and consistent with its profiles in other clinical scenarios.

Adjuvant Nivolumab/Chemo Reduces Recurrence Risk in Resected NSCLC

Roman Fabbricatore
September 12th 2025
Article